• Je něco špatně v tomto záznamu ?

Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy

M Stiborova, E Frei, VM Arlt, HH Schmeiser

. 2008 ; 658 (1-2) : 55-67.

Jazyk angličtina Země Nizozemsko

Typ dokumentu přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc11003176

Aristolochic acid (AA), a naturally occurring nephrotoxin and carcinogen, is associated with tumor development in patients suffering from Chinese herbs nephropathy (now termed aristolochic acid nephropathy, AAN) and may also be a cause for the development of a similar type of nephropathy, the Balkan endemic nephropathy (BEN). Major DNA adducts [7-(deoxyadenosin-N6-yl)-aristolactam and 7-(deoxyguanosin-N2-yl)aristolactam] formed from AA after reductive metabolic activation were found in renal tissues of patients with both diseases. Understanding which human enzymes are involved in AA activation and/or detoxication is important in the assessment of an individual's susceptibility to this plant carcinogen. This paper reviews major hepatic and renal enzymes responsible for AA-DNA adduct formation in humans. Phase I biotransformation enzymes play a crucial role in the metabolic activation of AA to species forming DNA adducts, while a role of phase II enzymes in this process is questionable. Most of the activation of AA in human hepatic microsomes is mediated by cytochrome P450 (CYP) 1A2 and, to a lower extent, by CYP1A1; NADPH:CYP reductase plays a minor role. In human renal microsomes NADPH:CYP reductase is more effective in AA activation. Prostaglandin H synthase (cyclooxygenase, COX) is another enzyme activating AA in human renal microsomes. Among the cytosolic reductases, NAD(P)H:quinone oxidoreductase (NQO1) is the most efficient in the activation of AA in human liver and kidney. Studies with purified enzymes confirmed the importance of CYPs, NADPH:CYP reductase, COX and NQO1 in the AA activation. The orientation of AA in the active sites of human CYP1A1, -1A2 and NQO1 was predicted from molecular modeling and explains the strong reductive potential of these enzymes for AA detected experimentally. We hypothesized that inter-individual variations in expressions and activities of enzymes activating AA may be one of the causes responsible for the different susceptibilities to this carcinogen reflected in the development of AA-induced nephropathies and associated urothelial cancer.

Citace poskytuje Crossref.org

000      
03712naa 2200409 a 4500
001      
bmc11003176
003      
CZ-PrNML
005      
20111210202232.0
008      
110225s2008 ne e eng||
009      
AR
024    __
$a 10.1016/j.mrrev.2007.07.003 $2 doi
035    __
$a (PubMed)17851120
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Stiborová, Marie, $d 1950-2020 $7 jo2005259907
245    10
$a Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy / $c M Stiborova, E Frei, VM Arlt, HH Schmeiser
314    __
$a Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, 128 40 Prague 2, Czech Republic. stiborov@natur.cuni.cz
520    9_
$a Aristolochic acid (AA), a naturally occurring nephrotoxin and carcinogen, is associated with tumor development in patients suffering from Chinese herbs nephropathy (now termed aristolochic acid nephropathy, AAN) and may also be a cause for the development of a similar type of nephropathy, the Balkan endemic nephropathy (BEN). Major DNA adducts [7-(deoxyadenosin-N6-yl)-aristolactam and 7-(deoxyguanosin-N2-yl)aristolactam] formed from AA after reductive metabolic activation were found in renal tissues of patients with both diseases. Understanding which human enzymes are involved in AA activation and/or detoxication is important in the assessment of an individual's susceptibility to this plant carcinogen. This paper reviews major hepatic and renal enzymes responsible for AA-DNA adduct formation in humans. Phase I biotransformation enzymes play a crucial role in the metabolic activation of AA to species forming DNA adducts, while a role of phase II enzymes in this process is questionable. Most of the activation of AA in human hepatic microsomes is mediated by cytochrome P450 (CYP) 1A2 and, to a lower extent, by CYP1A1; NADPH:CYP reductase plays a minor role. In human renal microsomes NADPH:CYP reductase is more effective in AA activation. Prostaglandin H synthase (cyclooxygenase, COX) is another enzyme activating AA in human renal microsomes. Among the cytosolic reductases, NAD(P)H:quinone oxidoreductase (NQO1) is the most efficient in the activation of AA in human liver and kidney. Studies with purified enzymes confirmed the importance of CYPs, NADPH:CYP reductase, COX and NQO1 in the AA activation. The orientation of AA in the active sites of human CYP1A1, -1A2 and NQO1 was predicted from molecular modeling and explains the strong reductive potential of these enzymes for AA detected experimentally. We hypothesized that inter-individual variations in expressions and activities of enzymes activating AA may be one of the causes responsible for the different susceptibilities to this carcinogen reflected in the development of AA-induced nephropathies and associated urothelial cancer.
650    _2
$a zvířata $7 D000818
650    _2
$a kyseliny aristolochové $x chemie $x metabolismus $7 D034341
650    _2
$a balkánská nefropatie $x metabolismus $x patologie $7 D001449
650    _2
$a biotransformace $7 D001711
650    _2
$a karcinogeny $x chemie $x metabolismus $7 D002273
650    _2
$a cytochrom P-450 CYP1A2 $x chemie $x metabolismus $7 D019388
650    _2
$a lidé $7 D006801
650    _2
$a chemické modely $7 D008956
650    _2
$a molekulární struktura $7 D015394
650    _2
$a rizikové faktory $7 D012307
650    _2
$a financování organizované $7 D005381
655    _2
$a přehledy $7 D016454
700    1_
$a Frei, Eva. $7 _AN036392
700    1_
$a Arlt, Volker M. $7 xx0074763
700    1_
$a Schmeiser, H. H.
773    0_
$t Mutation Research $w MED00003430 $g Roč. 658, č. 1-2 (2008), s. 55-67 $x 0027-5107
910    __
$a ABA008 $b B 1575 $y 7
990    __
$a 20110413115230 $b ABA008
991    __
$a 20111128104206 $b ABA008
999    __
$a ok $b bmc $g 830532 $s 695169
BAS    __
$a 3
BMC    __
$a 2008 $b 658 $c 1-2 $d 55-67 $i 0027-5107 $m Mutation research $n Mutat Res $x MED00003430
LZP    __
$a 2011-2B/ipme

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...